Back to search results

CRISPR-Edited CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

This study is testing a new treatment called CB-010 for adults with B cell non-Hodgkin lymphoma that has come back (relapsed) or hasn't responded to other treatments (refractory). CB-010 is a special type of cell therapy called CAR-T cell therapy, which uses your own immune cells to fight cancer. Before receiving CB-010, you will get chemotherapy with cyclophosphamide and fludarabine to prepare your body. The study aims to see how safe CB-010 is and how well it works to shrink tumors. You might be able to join if you are 18 or older, have this type of lymphoma, and meet certain health requirements. The study is currently recruiting 72 participants.

Study design
This is a first-in-human, open-label study with two parts. Part A will test increasing doses of CB-010 in a small group, and Part B will use the best dose in more participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will evaluate tumor response for up to 12 months after receiving CB-010.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04637763

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

UNKNOWN
PHASE1Ages 18+InterventionalTreatment
Caribou Biosciences, Inc.
~72 participants
Updated 2025-03-24 on ClinicalTrials.gov
What's tested:CB-010CyclophosphamideFludarabine

At a glance

Recruiting sites
35 of 38 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary outcome measures number of patients with dose-limiting toxicities (Part A).
Measured over 28 days following CB-010 infusion
+1 more outcome measured

Conditions

Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Lymphoma
B Cell Lymphoma
B Cell Non-Hodgkin's Lymphoma

Explore related trials

B-Cell Non-Hodgkin Lymphoma

NCT04637763

Where you'd take part

This study runs at 38 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Advent Health

    Orlando, Floridastudy coordinator listed

    Recruiting

  • Atlantic Health System

    Morristown, New Jerseystudy coordinator listed

    Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizonastudy coordinator listed

    Recruiting

  • Baylor Charles A. Sammons Cancer Center

    Dallas, Texasstudy coordinator listed

    Recruiting

  • Bone and Marrow Transplant Group of Georgia

    Atlanta, Georgiastudy coordinator listed

    Recruiting

  • Chao Family Comprehensive Cancer Center/University of California Irvine

    Orange, Californiastudy coordinator listed

    Recruiting

  • Epworth Healthcare

    Richmond, Victoria, Australiastudy coordinator listed

    Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Socorro Portella, MD
[email protected]
973 866 7567
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age greater than or equal to 18 at the time of enrollment
Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
Eastern Cooperative Oncology Group performance status 0 or 1
Adequate hematologic, renal, liver, cardiac and pulmonary organ function

Exclusion

Prior therapy with an anti-CD19 targeting agent
Active or chronic graft versus host disease requiring therapy
Prior allogeneic stem cell transplantation
Central nervous system (CNS) lymphoma, prior CNS malignancy
Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
Primary immunodeficiency
Current or expected need for systemic corticosteroid therapy
Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
Unwillingness to follow extended safety monitoring

What this trial measures

  • Primary outcome measures number of patients with dose-limiting toxicities (Part A).28 days following CB-010 infusion

    Incidence of adverse events defined as dose-limiting toxicities with onset within 28 days after CB-010 infusion.

  • Primary outcome evaluates tumor response (Part B)Up to 12 months

    The primary endpoint is objective response rate.